Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications

Therapeutic Advances in Medical Oncology
Can KüçükHua You

Abstract

Natural killer/T-cell lymphoma (NKTCL) is an aggressive malignancy that usually presents in the upper aerodigestive tract. This malignancy shows substantial geographic variability in incidence, and is characterized by Epstein-Barr virus (EBV) infections. Epigenetic aberrations may dysregulate the expression of genes involved in different hallmarks of cancer. A growing body of evidence underscores the importance of epigenetic aberrations in the pathogenesis of NKTCL. Promoter hypermethylation is a common epigenetic mechanism for the inactivation of tumour suppressor genes. Several epigenetically silenced tumour suppressor candidates (e.g. PRDM1, BIM) were identified in this aggressive cancer using locus-specific and genome-wide promoter methylation analyses. Importantly, genes involved in epigenetic modifications were identified to be mutated (e.g. KMT2D) or methylated (e.g. TET2) in NKTCL patients, which may contribute to pathogenesis through global alterations in chromatin states. Cancer-associated microRNAs, some of which are expressed by EBV, and long noncoding RNAs have been observed to be dysregulated in NKTCL. This review focuses on studies investigating epigenetic aberrations in NKTCL to bolster our overall understanding...Continue Reading

References

May 28, 1987·The New England Journal of Medicine·I Pastan, M Gottesman
Sep 17, 1998·Nature·R Z ChenR Jaenisch
Mar 4, 2000·Nature Genetics·S A GaytherC Caldas
Apr 26, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·T LiK Aozasa
May 19, 2001·European Journal of Biochemistry·S R Grossman
Jan 12, 2002·The American Journal of Pathology·Lisa Lai Ping SiuYok-Lam Kwong
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Jul 4, 2002·Oncogene·Tetsuya TakakuwaKatsuyuki Aozasa
Jul 12, 2002·Proceedings of the National Academy of Sciences of the United States of America·Chi-Neu TsaiYu-Sun Chang
Dec 13, 2002·Nature·Sandrine Etienne-Manneville, Alan Hall
Apr 19, 2003·Science·Amir EdenRudolf Jaenisch
Apr 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stefan CostineanCarlo M Croce
Dec 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Xu-Bao ShiRalph W deVere White
Jan 11, 2008·Nature·Sohail F TavazoieJoan Massagué
Jul 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Patrick S MitchellMuneesh Tewari
Aug 30, 2008·Mutation Research·Jeffrey A Simon, Carol A Lange
Oct 17, 2008·PloS One·Ming LuQinghua Cui
Feb 4, 2009·Nature Reviews. Genetics·Tim R MercerJohn S Mattick
Mar 18, 2009·Clinical Lung Cancer·Guilherme RabinowitsGoetz H Kloecker
Oct 15, 2010·Nature Biotechnology·Theresa K KellyPeter A Jones
Feb 22, 2011·TheScientificWorldJournal·Katsuyuki Aozasa, Mona A A Zaki
Feb 24, 2011·Current Molecular Medicine·J R TanK Jeyaseelan
Mar 10, 2011·Nature Medicine·Manuel Rodríguez-Paredes, Manel Esteller
Apr 16, 2011·Blood·Francine M FossKensei Tobinai
May 26, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jin Ho PaikChul-Woo Kim
Jun 8, 2011·PloS One·Cheng-Chung LeeAndrew H-J Wang
Sep 20, 2011·Molecular Cell·Kevin C Wang, Howard Y Chang
Dec 7, 2011·Proceedings of the National Academy of Sciences of the United States of America·Can KüçükWing C Chan

❮ Previous
Next ❯

Citations

Oct 17, 2020·Cancer Management and Research·Mei ZengYan Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
MeDIP-chip
acetylation

Software Mentioned

MeDIP

Related Concepts

Related Feeds

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.